Discovery of indole inhibitors of chemokine receptor 9 (CCR9)

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3322-3325. doi: 10.1016/j.bmcl.2016.05.043. Epub 2016 May 14.

Abstract

Irritable bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are serious chronic diseases affecting millions of patients worldwide. Studies of human chemokine biology has suggested C-C chemokine receptor 9 (CCR9) may be a key mediator of pro-inflammatory signaling. Discovery of agents that inhibit CCR9 may lead to new therapies for CD and UC patients. Herein we describe the evolution of a high content screening hit (1) into potent inhibitors of CCR9, such as azaindole 12.

Keywords: Crohn’s disease (CD); C–C chemokine receptor 9 (CCR9); Irritable bowel disease (IBD); Ulcerative colitis (UC).

MeSH terms

  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / metabolism
  • Crohn Disease / drug therapy*
  • Crohn Disease / metabolism
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • Humans
  • Indoles / chemical synthesis
  • Indoles / chemistry
  • Indoles / pharmacology*
  • Molecular Structure
  • Receptors, CCR / antagonists & inhibitors*
  • Receptors, CCR / metabolism
  • Structure-Activity Relationship

Substances

  • CC chemokine receptor 9
  • Indoles
  • Receptors, CCR
  • indole